Respiratory medicine
-
Respiratory medicine · Nov 2013
Multicenter Study Observational StudyAssessment of asthma control: the SERENA study.
Several studies suggest that many asthmatic subjects have uncontrolled asthma. The control of asthma is now considered the major goal of therapy. ⋯ This study highlights the importance in clinical practice of a periodic assessment by a validated asthma control instrument and exacerbations/health care contacts during previous year. Clinicians should be aware that a significant proportion of patients can have uncontrolled asthma, despite regular pharmacological treatment.
-
Respiratory medicine · Nov 2013
Multicenter Study Controlled Clinical TrialFunctional and psychological variables both affect daily physical activity in COPD: a structural equations model.
Daily physical activity (DPA) level is reduced in patients with COPD. The aim of this study was to investigate the association of DPA with functional and psychological variables in these patients. ⋯ ClinicalTrials.gov, NCT00614796.
-
Respiratory medicine · Nov 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD.
To evaluate the efficacy and tolerability of the selective CRTh2 (DP2) receptor antagonist AZD1981 compared with placebo in patients with moderate to severe COPD. ⋯ There was no beneficial clinical effect of AZD1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD1981 was well tolerated and no safety concerns were identified.
-
Respiratory medicine · Oct 2013
Randomized Controlled Trial Multicenter StudySafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium (NVA237) for the treatment of chronic obstructive pulmonary disease (COPD). We investigated the safety and efficacy of QVA149 over 52 weeks. ⋯ QVA149 demonstrated a good safety and tolerability profile, providing rapid and sustained bronchodilation over 52 weeks in patients with moderate-to-severe COPD. ClinicalTrials.gov identifier: NCT01120717.
-
Respiratory medicine · Oct 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
To examine the efficacy and safety of the once-daily, inhaled, long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies in patients with chronic obstructive pulmonary disease (COPD). ⋯ Once-daily UMEC/VI 62.5/25 mcg was well tolerated and provided clinically-significant improvements in lung function and symptoms in patients with COPD.